EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Developments in Human Papillomavirus (HPV) Vaccinology

Anna-Lise Williamson iD

Viruses · 26.06.2023 · 15 (7) · 1440

DOI: 10.3390/v15071440 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 26.06.2023. Verfasst von Anna-Lise Williamson. Beteiligte Einrichtung: Institute of Infectious Disease and Molecular Medicine/SAMRC Gynaecological Cancer Research Centre/Division of Medical Virology, Department of Pathol…. Hauptthemen laut MEDLINE: Papillomavirus Infections, Uterine Cervical Neoplasms, Papillomavirus Vaccines. Die Arbeit wurde bisher 190-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human papillomavirus (HPV) is causally associated with 5% of cancers, including cancers of the cervix, penis, vulva, vagina, anus and oropharynx. The most carcinogenic HPV is HPV-16, which dominates the types causing cancer. There is also sufficient evidence that HPV types 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 cause cervical cancer. The L1 protein, which, when assembled into virus-like particles, induces HPV-type-specific neutralising antibodies, forms the basis of all commercial HPV vaccines. There are six licensed prophylactic HPV vaccines: three bivalent, two quadrivalent and one nonavalent vaccine. The bivalent vaccines protect from HPV types 16 and 18, which are associated with more than 70% of cervical cancers. Prophylactic vaccination targets children before sexual debut, but there are now catch-up campaigns, which have also been shown to be beneficial in reducing HPV infection and disease. HPV vaccination of adults after treatment for cervical lesions or recurrent respiratory papillomatosis has impacted recurrence. Gender-neutral vaccination will improve herd immunity and prevent infection in men and women. HPV vaccines are immunogenic in people living with HIV, but more research is needed on the long-term impact of vaccination and to determine whether further boosters are required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsUterine Cervical NeoplasmsPapillomavirus VaccinesAdultMaleChildHumansFemaleHuman Papillomavirus VirusesVaccinologyHuman papillomavirus 16Vaccines, Combined

Stichwörter der Autor:innen

HPV vaccineanal cancercervical cancerpapillomavirus

Substanzen

Papillomavirus VaccinesVaccines, Combined

Autor:innen und Institutionen

  • Institute of Infectious Disease and Molecular Medicine/SAMRC Gynaecological Cancer Research Centre/Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.

ORCID-Profile: Anna-Lise Williamson

Zitieren

APA

Williamson, A. L. (2023). Recent Developments in Human Papillomavirus (HPV) Vaccinology. Viruses, 15(7), 1440. https://doi.org/10.3390/v15071440

Vancouver

Williamson AL. Recent Developments in Human Papillomavirus (HPV) Vaccinology. Viruses. 2023;15(7):1440. doi:10.3390/v15071440

BibTeX
@article{Williamson2023,
  author = {Williamson, Anna-Lise},
  title = {Recent Developments in Human Papillomavirus (HPV) Vaccinology},
  journal = {Viruses},
  year = {2023},
  volume = {15},
  number = {7},
  pages = {1440},
  doi = {10.3390/v15071440}
}
Kostenlos starten →